Dragonfly Therapeutics Inc. has expanded its executive leadership team with the addition of Dr. Susan Altschuller as Chief Financial Officer.

About Susan Altschuller Ph.D., MBA

Altschuller is a seasoned executive with more than two decades of strategic and financial leadership experience at leading pharmaceutical and biotechnology companies. Most recently, she served as the chief financial officer of Cerevel Therapeutics, a biotechnology company developing therapies for neuroscience diseases, until its acquisition by AbbVie.
 
Before Cerevel, Altschuller was chief financial officer of ImmunoGen, supporting the oncology company’s first commercial launch. Prior to ImmunoGen she worked at Alexion, where she was vice president and head of investor relations and later, head of enterprise finance. Altschuller has also served as head of investor relations at Bioverativ, a hemophilia spin-off from Biogen, and held various positions in Biogen finance and as senior consultant at the Frankel Group.
 
She received a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. Altschuller has served as audit chair on the Board of Directors of Vestaron Corporation and Mural Oncology and is a founding Board member of the HNRNP Family Foundation.
 
“We are delighted that Susan has joined Dragonfly,” said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. “Her leadership growing successful biopharma companies comes at an exciting time as Dragonfly expands our clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease. Susan’s powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercializing leading immune-engaging therapeutics.”